Metrics and benchmarks for HIV transition - Authors' reply

Affiliations

¹ Center for Infectious Disease Modeling and Analysis, Yale School of Public Health, New Haven, CT, USA.
² Center for Infectious Disease Modeling and Analysis, Yale School of Public Health, New Haven, CT, USA; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.
³ Center for Infectious Disease Modeling and Analysis, Yale School of Public Health, New Haven, CT, USA. Electronic address: alison.galvani@gmail.com.

Comment

Abhishek Pandey et al. Lancet HIV. 2019 Mar.

. 2019 Mar;6(3):e150.

doi: 10.1016/S2352-3018(19)30049-9.

¹ Center for Infectious Disease Modeling and Analysis, Yale School of Public Health, New Haven, CT, USA.
² Center for Infectious Disease Modeling and Analysis, Yale School of Public Health, New Haven, CT, USA; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.
³ Center for Infectious Disease Modeling and Analysis, Yale School of Public Health, New Haven, CT, USA. Electronic address: alison.galvani@gmail.com.

No abstract available

Comment on

Defining control of HIV epidemics.
Galvani AP, Pandey A, Fitzpatrick MC, Medlock J, Gray GE. Galvani AP, et al. Lancet HIV. 2018 Nov;5(11):e667-e670. doi: 10.1016/S2352-3018(18)30178-4. Epub 2018 Oct 9. Lancet HIV. 2018. PMID: 30314745
Metrics and benchmarks for HIV transition.
Ghys PD, Over M, Hallett TB, Mahy M, Godfrey-Faussett P. Ghys PD, et al. Lancet HIV. 2019 Mar;6(3):e150. doi: 10.1016/S2352-3018(19)30050-5. Lancet HIV. 2019. PMID: 30846054 No abstract available.